218 related articles for article (PubMed ID: 19637311)
41. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
[TBL] [Abstract][Full Text] [Related]
42. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.
Sherlock M; Fernandez-Rodriguez E; Alonso AA; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
J Clin Endocrinol Metab; 2009 Apr; 94(4):1255-63. PubMed ID: 19158203
[TBL] [Abstract][Full Text] [Related]
43. The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs.
Colao A; Pivonello R; Cappabianca P; Auriemma RS; De Martino MC; Ciccarelli A; de Divitiis E; Lombardi G
J Endocrinol Invest; 2003; 26(10 Suppl):53-6. PubMed ID: 15497660
[TBL] [Abstract][Full Text] [Related]
44. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy.
Colao A; Pivonello R; Galderisi M; Cappabianca P; Auriemma RS; Galdiero M; Cavallo LM; Esposito F; Lombardi G
J Clin Endocrinol Metab; 2008 Jul; 93(7):2639-46. PubMed ID: 18445662
[TBL] [Abstract][Full Text] [Related]
45. [Somatostatin analogs in the clinical management of pituitary neoplasms].
Colao A; Dorato M; Pulcrano M; Rossi FW; Auriemma RS; Lombardi G; Lastoria S
Minerva Endocrinol; 2001 Sep; 26(3):181-91. PubMed ID: 11753242
[TBL] [Abstract][Full Text] [Related]
46. Somatostatin analogs in the treatment of acromegaly.
Lamberts SW; Reubi JC; Krenning EP
Endocrinol Metab Clin North Am; 1992 Sep; 21(3):737-52. PubMed ID: 1355729
[TBL] [Abstract][Full Text] [Related]
47. ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas.
Vieria Neto L; Wildemberg LE; Colli LM; Kasuki L; Marques NV; Moraes AB; Gasparetto EL; Takiya CM; Castro M; Gadelha MR
PLoS One; 2013; 8(10):e77406. PubMed ID: 24098585
[TBL] [Abstract][Full Text] [Related]
48. Novel pathway for somatostatin analogs in patients with acromegaly.
Gadelha MR; Kasuki L; Korbonits M
Trends Endocrinol Metab; 2013 May; 24(5):238-46. PubMed ID: 23270713
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature.
Suda K; Inoshita N; Iguchi G; Fukuoka H; Takahashi M; Nishizawa H; Yamamoto M; Yamada S; Takahashi Y
Endocr J; 2013; 60(4):507-15. PubMed ID: 23291436
[TBL] [Abstract][Full Text] [Related]
50. Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German Acromegaly Register.
Petersenn S; Buchfelder M; Reincke M; Strasburger CM; Franz H; Lohmann R; Quabbe HJ; Plöckinger U;
Eur J Endocrinol; 2008 Nov; 159(5):525-32. PubMed ID: 18755874
[TBL] [Abstract][Full Text] [Related]
51. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
52. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly.
Andries M; Glintborg D; Kvistborg A; Hagen C; Andersen M
Clin Endocrinol (Oxf); 2008 Mar; 68(3):473-80. PubMed ID: 17941902
[TBL] [Abstract][Full Text] [Related]
53. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
Caron P; Morange-Ramos I; Cogne M; Jaquet P
J Clin Endocrinol Metab; 1997 Jan; 82(1):18-22. PubMed ID: 8989225
[TBL] [Abstract][Full Text] [Related]
54. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
Karavitaki N; Turner HE; Adams CB; Cudlip S; Byrne JV; Fazal-Sanderson V; Rowlers S; Trainer PJ; Wass JA
Clin Endocrinol (Oxf); 2008 Jun; 68(6):970-5. PubMed ID: 18031313
[TBL] [Abstract][Full Text] [Related]
55. Investigational therapies for acromegaly.
Grasso LF; Pivonello R; Colao A
Expert Opin Investig Drugs; 2013 Aug; 22(8):955-63. PubMed ID: 23731031
[TBL] [Abstract][Full Text] [Related]
56. Somatostatin analogs in acromegaly.
Freda PU
J Clin Endocrinol Metab; 2002 Jul; 87(7):3013-8. PubMed ID: 12107192
[No Abstract] [Full Text] [Related]
57. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly.
Neggers SJ; van Aken MO; Janssen JA; Feelders RA; de Herder WW; van der Lely AJ
J Clin Endocrinol Metab; 2007 Dec; 92(12):4598-601. PubMed ID: 17895318
[TBL] [Abstract][Full Text] [Related]
58. Preoperative somatostatin analogs treatment in acromegalic patients with macroadenomas. A meta-analysis.
Zhang L; Wu X; Yan Y; Qian J; Lu Y; Luo C
Brain Dev; 2015 Feb; 37(2):181-90. PubMed ID: 24815226
[TBL] [Abstract][Full Text] [Related]
59. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
[TBL] [Abstract][Full Text] [Related]
60. Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.
Barkan AL; Kelch RP; Hopwood NJ; Beitins IZ
J Clin Endocrinol Metab; 1988 Jan; 66(1):16-23. PubMed ID: 2891720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
